RxSight (RXST)

• Market cap: $1.02B
• 1 day: -0.28%
• 5 days: 1.94%
• 1 month: -6.50%
• 3 months: -27.12%
• 6 months: -46.60%
• Year to date: -27.12%
• 1 year: -50.11%
• 5 years: 57.38%
• 10 years: 57.38%
• Sector: Healthcare
• Industry: Ophthalmic Goods

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

1,042% more call options, than puts

Call options by funds: $19.8M | Put options by funds: $1.73M

50% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]

35% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 62

1.62% more ownership

Funds ownership: 86.03% [Q3] → 87.65% (+1.62%) [Q4]

5% less first-time investments, than exits

New positions opened: 39 | Existing positions closed: 41

1% less funds holding

Funds holding: 214 [Q3] → 211 (-3) [Q4]

28% less capital invested

Capital invested by funds: $1.69B [Q3] → $1.21B (-$473M) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $28 11% upside
• Avg. target: $36 45% upside
• High target: $43 71% upside

5 analyst ratings

• positive: 3 60%
• neutral: 2 40%
• negative: 0 0%

B of A Securities Craig Bijou 50% 1-year accuracy 5 / 10 met price target	43% upside $36	Buy Maintained	21 Mar 2025
Stifel Thomas Stephan 33% 1-year accuracy 5 / 15 met price target	11% upside $28	Hold Maintained	19 Mar 2025
JP Morgan Robbie Marcus 53% 1-year accuracy 10 / 19 met price target	59% upside $40	Overweight Maintained	26 Feb 2025
Wells Fargo Larry Biegelsen 36% 1-year accuracy 17 / 47 met price target	39% upside $35	Equal-Weight Maintained	26 Feb 2025
Needham David Saxon 37% 1-year accuracy 24 / 65 met price target	71% upside $43	Buy Reiterated	26 Feb 2025